Harmony Biosciences officer plans 1,800-share sale
An officer of Harmony Biosciences filed a Rule 144 notice to sell 1,800 shares after exercising stock options, disclosing additional recent 10b5-1 sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. (HRMY) has an officer, Kumar Budur, filing a notice of proposed sale of restricted or control securities under Rule 144. The filing covers up to 1,800 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on September 16, 2026, in connection with a cash exercise of stock options.
The filing also lists prior Rule 10b5-1 sales of common stock by Kumar Budur during the preceding three months, including separate transactions of 5,500 shares, 22,954 shares, and 5,500 shares on September 8 and September 4, 2026, respectively, with stated aggregate sale proceeds for each transaction.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 regulatory
Exercise of Stock Options financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for Harmony Biosciences (HRMY) by Kumar Budur report?
What recent 10b5-1 sales by Kumar Budur in HRMY stock are disclosed?
Which broker is handling the proposed Rule 144 sale for Harmony Biosciences (HRMY)?
AI-generated analysis. How Rhea-AI works. Not financial advice.